| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The goal of this project is to generate a novel cancer therapy using the next generation chimeric antigen receptor (CAR)-expressing T cell that exerts anti-cancer effect more effectively than the conventional one. So far, the following results have been obtained;
1) The next generation CAR-T cell that concomitantly expresses CAR specific to a tumor antigen, a cytokine committing to T cell survival, and a chemokine inducing migration of T cells was generated. 2) The next generation CAR-T cells exerted more potent anti-tumor effects than the conventional one in several murine tumor models. 3) Molecular mechanisms underlying the potent tumoricidal efficacy of the next generation CAR-T cells were elucidated.
|
